InvestSMART

ChemGenex Pharmaceuticals Ltd (ASX: CXS) - Announcements

DELISTED - Current share price for CXS : $0.700

ASX company news and announcements for ChemGenex Pharmaceuticals Ltd (CXS) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All ChemGenex Pharmaceuticals Ltd (CXS) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than ChemGenex Pharmaceuticals Ltd (CXS), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for ChemGenex Pharmaceuticals Ltd (CXS)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Positive Results for Ceflatonin Presented at ASH Meeting 11 Dec 2006 8:29AM $0.626 $0.700 risen by 11.86%
- FDA Grants Fast Track Status for Ceflatonin 15 Nov 2006 9:19AM $0.577 $0.700 risen by 21.34%
- Initial Patients Treated in Phase 2/3 Trial of Ceflatonin 20 Sep 2006 9:49AM $0.430 $0.700 risen by 62.72%
- Preliminary Final Report & Full Year Accounts 29 Aug 2006 5:51PM $0.406 $0.700 risen by 72.50%
- Publication of Two New Clinical Studies 2 Aug 2006 9:42AM $0.440 $0.700 risen by 59.09%
- Media Coverage of heart failure linked to Gleevec 26 Jul 2006 11:04AM $0.411 $0.700 risen by 70.44%
- Alliance to identify CML Patients with the T3151 Mutation 26 Jun 2006 9:47AM $0.372 $0.700 risen by 88.37%
- Reinstatement to Official Quotation 8 May 2006 10:34AM $0.538 $0.700 risen by 30.16%
- Completes $A15 Million Capital Raising 8 May 2006 10:33AM $0.538 $0.700 risen by 30.16%
- Suspension from Official Quotation 3 May 2006 9:17AM n/a $0.700 n/a
- Trading Halt 1 May 2006 9:30AM n/a $0.700 n/a
- New preclinical research supports Ceflatonin 23 Mar 2006 9:42AM $0.606 $0.700 risen by 15.47%
- US FDA grants Orphan Drug status for Ceflatonin for CML 20 Mar 2006 9:58AM $0.636 $0.700 risen by 10.13%
- Half Yearly Report/Half Year Accounts 10 Mar 2006 10:44AM $0.597 $0.700 risen by 17.35%
- Granted US Patent for Ceflatonin in Gleevec-Resistant 18 Jan 2006 10:48AM $0.611 $0.700 risen by 14.55%
- New Diabetes Research Contract With Merck KGaA 17 Jan 2006 12:39PM $0.606 $0.700 risen by 15.47%
- Compelling Phase 2 Data published in Leading Journal 12 Dec 2005 10:02AM $0.621 $0.700 risen by 12.74%
- ChemGenex Team Pinpoints Inflammation Gene 10 Oct 2005 9:56AM $0.528 $0.700 risen by 32.58%
- New Phase 2 Trial of Ceflatonin 5 Oct 2005 10:03AM $0.489 $0.700 risen by 43.18%
- Personalised Medicine Clinical Trial Expanded 27 Sep 2005 9:56AM $0.518 $0.700 risen by 35.08%
- Preliminary Final Report 30 Aug 2005 10:00AM $0.557 $0.700 risen by 25.58%
- Two New Studies by ChemGenex 27 Jul 2005 11:40AM $0.587 $0.700 risen by 19.31%
- Strategy for Reg-Directed clinical trials for Ceflatonin 18 Jul 2005 12:47PM $0.641 $0.700 risen by 9.29%
- Alliance to accelerate Ceflatonin Clinical Development 28 Jun 2005 8:30AM $0.689 $0.700 risen by 1.54%
- To Receive Significant Milestone Payment from Vernalis 23 Feb 2005 9:48AM $0.606 $0.700 risen by 15.47%

76 - 100 of 105 results

Page 4 of 5

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.